Glaukos Corp (GKOS) Stock Price, Quote & News

Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patient...

Industry: Medical Devices

Sector: Healthcare

Phone: 949 367 9600

Fax: 949 367 9984

Website: www.glaukos.com

Address:

One Glaukos Way, Aliso Viejo, United States

erevnon Feb. 18 at 1:10 PM

Needham maintains Glaukos $GKOS at Buy and raises the price target from $125 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Estimize Feb. 18 at 11:03 AM

$GKOS reported -0.28 EPS and 143.12 revenue for Q4. http://www.estimize.com/intro/gkos?chart=historical&metric_name=eps&utm_content=GKOS&ut

0 · Reply

erevnon Feb. 18 at 10:27 AM

BTIG reiterates Glaukos $GKOS at Buy and maintains the price target at https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

StocktwitsEarnings Feb. 17 at 9:17 PM

$GKOS Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$2.32 down -286.67% YoY • Reported revenue of $143.12M up 35.66% YoY • Glaukos reaffirmed its 2026 net sales guidance, expecting revenue in the range of $600M to $620M based on current foreign currency exchange rates.

0 · Reply

DonCorleone77 Feb. 17 at 7:21 PM

$PANW $CDNS $TOL $GKOS Some notable companies reporting after the market close, with earnings consensus estimates:** - Palo Alto (PANW), consensus 94c - Cadence Design (CDNS), consensus $1.91 - Toll Brothers (TOL), consensus $2.11 - Glaukos (GKOS), consensus (20c)

0 · Reply

Estimize Feb. 17 at 4:00 PM

$GKOS reports after the close, Estimize Consensus +0.02 EPS and +6.48M Revs compared to WS http://www.estimize.com/gkos/fq4-2025?utm_conten

0 · Reply

SuperGreenToday Feb. 10 at 7:34 PM

$GKOS Share Price: $113.89 Contract Selected: Jul 17, 2026 $115 Calls Buy Zone: $12.92 – $15.96 Target Zone: $23.00 – $28.11 Potential Upside: 68% ROI Time to Expiration: 156 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

VolumeSpreadAnalysis Feb. 4 at 12:05 PM

$GKOS is a medical device company in ophthalmology; its growth is driven by its flagship stent for glaucoma, but payer reimbursement dynamics are critical.

0 · Reply

Kingofstocks0001 Feb. 2 at 3:33 PM

$GKOS great growth

0 · Reply

ZacksResearch Jan. 29 at 2:44 PM

$GKOS up 32.2% in 6 months — but can it sustain the momentum? 💡 🔹 Positioned for growth with interventional glaucoma shift 🔹 Synergies between iDose TR & iStent infinite boosting prospects 🔹 Long-term leverage despite short-term margin pressure Is this a long-term winner? Full analysis here 👉 https://www.zacks.com/stock/news/2825023/heres-why-you-should-retain-glaukos-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2825023-body-30881&ADID=SYND_STOCKTWITS_TWEET_2_2825023_BODY_30881

0 · Reply

Glaukos Corporation (GKOS) Q4 2025 Earnings Call Transcript

Feb 17, 2026, 4:05 PM EST - 16 hours ago

Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results

Feb 3, 2026, 10:00 AM EST - 14 days ago

Alger Weatherbie Specialized Growth Fund Q4 2025 Winners And Laggards

ACAD AI CNS FSV KTOS MSCI NTRA

Jan 29, 2026, 10:30 PM EST - 19 days ago

Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

ABBV ABVX CVLT FIX FTAI GMAB HLI

Jan 28, 2026, 7:00 AM EST - 21 days ago

Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR

Jan 20, 2026, 7:00 AM EST - 4 weeks ago

Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17

Jan 13, 2026, 11:55 PM EST - 5 weeks ago

Glaukos Corporation (GKOS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 4:05 PM EST - 5 weeks ago

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance

Dec 16, 2025, 7:00 AM EST - 2 months ago

Glaukos Announces Participation in J.P. Morgan Healthcare Conference

Dec 3, 2025, 5:23 PM EST - 2 months ago

Glaukos Corporation (GKOS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 11, 2025, 1:21 PM EST - 3 months ago

Glaukos Corporation (GKOS) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 3, 2025, 7:00 AM EST - 3 months ago

Glaukos Announces Participation in Upcoming Investor Conferences

Oct 30, 2025, 12:06 AM EDT - 3 months ago

Glaukos Corporation (GKOS) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 4:05 PM EDT - 3 months ago

Glaukos Announces Third Quarter 2025 Financial Results

Oct 20, 2025, 7:10 AM EDT - 4 months ago

US FDA approves Glaukos' new eye therapy

Oct 20, 2025, 7:00 AM EDT - 4 months ago

Glaukos Announces FDA Approval of Epioxa™

Oct 14, 2025, 7:00 AM EDT - 4 months ago

Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting

Oct 8, 2025, 7:00 AM EDT - 4 months ago

Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29

Sep 25, 2025, 4:05 PM EDT - 5 months ago

Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama

Aug 13, 2025, 7:00 AM EDT - 6 months ago

Glaukos Announces Participation in Wells Fargo Healthcare Conference

Jul 31, 2025, 5:15 AM EDT - 7 months ago

Glaukos Corporation (GKOS) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 4:05 PM EDT - 7 months ago

Glaukos Announces Second Quarter 2025 Financial Results

Jul 9, 2025, 7:00 AM EDT - 8 months ago

Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30

Jun 25, 2025, 4:05 PM EDT - 8 months ago

Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies

Jun 25, 2025, 7:00 AM EDT - 8 months ago

Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell

Apr 30, 2025, 10:05 PM EDT - 10 months ago

Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 4:05 PM EDT - 10 months ago

Glaukos Announces First Quarter 2025 Financial Results

Apr 29, 2025, 11:30 AM EDT - 10 months ago

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

ACLX BSX DHR INSM ISRG LLY RDNT

$Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting$

Apr 23, 2025, 7:00 AM EDT - 10 months ago

Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Apr 16, 2025, 7:00 AM EDT - 11 months ago

Glaukos Announces the Release of its 2024 Sustainability Report

Apr 9, 2025, 7:00 AM EDT - 11 months ago

Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

Mar 11, 2025, 7:00 AM EDT - 1 year ago

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

Feb 24, 2025, 9:12 AM EST - 1 year ago

FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery

Feb 24, 2025, 7:00 AM EST - 1 year ago

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

Feb 21, 2025, 10:27 AM EST - 1 year ago

Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition

Feb 21, 2025, 4:29 AM EST - 1 year ago

Glaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 4:05 PM EST - 1 year ago

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

Jan 23, 2025, 7:00 AM EST - 1 year ago

Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

Jan 14, 2025, 4:05 PM EST - 1 year ago

Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform

Dec 31, 2024, 8:59 AM EST - 1 year ago

Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday

Dec 23, 2024, 7:00 AM EST - 1 year ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

Dec 21, 2024, 7:04 AM EST - 1 year ago

Glaukos: Still Bullish, But Embedded Expectations Are Now High

Dec 17, 2024, 7:00 AM EST - 1 year ago

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Dec 2, 2024, 2:29 PM EST - 1 year ago

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

ISRG NVRO SYK

Nov 5, 2024, 12:21 PM EST - 1 year ago

Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds

Nov 4, 2024, 11:03 PM EST - 1 year ago

Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 4:05 PM EST - 1 year ago

Glaukos Announces Third Quarter 2024 Financial Results

Oct 16, 2024, 4:05 PM EDT - 1 year ago

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety

Oct 14, 2024, 7:00 AM EDT - 1 year ago

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting

Oct 9, 2024, 7:00 AM EDT - 1 year ago

Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4

erevnon Feb. 18 at 1:10 PM

Needham maintains Glaukos $GKOS at Buy and raises the price target from $125 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Estimize Feb. 18 at 11:03 AM

$GKOS reported -0.28 EPS and 143.12 revenue for Q4. http://www.estimize.com/intro/gkos?chart=historical&metric_name=eps&utm_content=GKOS&ut

0 · Reply

erevnon Feb. 18 at 10:27 AM

BTIG reiterates Glaukos $GKOS at Buy and maintains the price target at https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

StocktwitsEarnings Feb. 17 at 9:17 PM

0 · Reply

DonCorleone77 Feb. 17 at 7:21 PM

0 · Reply

Estimize Feb. 17 at 4:00 PM

$GKOS reports after the close, Estimize Consensus +0.02 EPS and +6.48M Revs compared to WS http://www.estimize.com/gkos/fq4-2025?utm_conten

0 · Reply

SuperGreenToday Feb. 10 at 7:34 PM

0 · Reply

VolumeSpreadAnalysis Feb. 4 at 12:05 PM

$GKOS is a medical device company in ophthalmology; its growth is driven by its flagship stent for glaucoma, but payer reimbursement dynamics are critical.

0 · Reply

Kingofstocks0001 Feb. 2 at 3:33 PM

$GKOS great growth

0 · Reply

ZacksResearch Jan. 29 at 2:44 PM

0 · Reply

ZacksResearch Jan. 29 at 1:44 PM

Hold onto $GKOS — this story isn’t done yet. 👀 Glaukos is positioned for growth as interventional glaucoma adoption expands, iDose and iStent synergies build, and scale drives operating leverage — even with margin pressure in the mix. That’s a long-term setup investors shouldn’t ignore. See why retaining GKOS still makes sense right now 👉 https://www.zacks.com/stock/news/2825023/heres-why-you-should-retain-glaukos-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2825023-teaser-30877&ADID=SYND_STOCKTWITS_TWEET_2_2825023_TEASER_30877

0 · Reply

notreload_ai Jan. 28 at 2:58 PM

$GKOS receives FDA approval allowing patients to receive multiple iDose TR treatments for glaucoma management, expanding treatment options. https://notreload.xyz/fda-approves-repeat-treatment-for-idose-tr-glaucoma-implant/

0 · Reply

OfficialStocktwitsUser Jan. 27 at 11:57 PM

$GKOS RSI: 56.57, MACD: 3.5246 Vol: 5.66, MA20: 115.79, MA50: 109.91 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Kingofstocks0001 Jan. 27 at 4:24 PM

$GKOS about to fly

0 · Reply

ZemoriSwings Jan. 26 at 6:49 PM

$GKOS

0 · Reply

JFDI Jan. 26 at 6:19 PM

$GKOS prolly worth stalking

0 · Reply

IN0V8 Jan. 22 at 3:37 PM

$GKOS Stifel raises target price to $160 from $115

1 · Reply

erevnon Jan. 22 at 2:57 PM

Stifel maintains Glaukos $GKOS at Buy and raises the price target from $115 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Stackdoe101 Jan. 16 at 7:26 PM

$GKOS $150

0 · Reply

Kingofstocks0001 Jan. 14 at 4:29 PM

$GKOS This is undervalued. Easily will reach $170 in 3 months. Wait for the 70% gain.

0 · Reply

notreload_ai Jan. 14 at 4:08 PM

$GKOS shares fell after Q4 iDose sales growth disappointed investors, though the company maintained its 2026 revenue guidance of $600-620 million. https://notreload.xyz/glaukos-stock-falls-on-slower-idose-product-growth-in-q4/

0 · Reply

EmoDaddy Jan. 14 at 3:57 PM

$GKOS debt free is the way to be!

0 · Reply

Market Cap	6.29B
Revenue (ttm)	383.48M
Net Income (ttm)	-146.37M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-38.17%
Debt to Equity Ratio	0.00

Volume	1,263,524
Avg Vol	771,446
Day's Range	N/A - N/A
Shares Out	57.44M
Stochastic %K	10%
Beta	0.70
Analysts	Strong Sell
Price Target	$132.71